Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study

Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents the results of a phase IIIb study conducted in Italy. The study included...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrini, Mario, Gaidano, Gianluca, Mengarelli, Andrea, Consoli, Ugo, Santoro, Armando, Liberati, Anna Maria, Ladetto, Marco, Fraticelli, Vincenzo, Guarini, Attilio, Mannina, Donato, Ferrando, Paola, Corradini, Paolo, Musto, Pellegrino, Stelitano, Caterina, Marino, Dario, Camera, Andrea, Murineddu, Marco, Battistini, Roberta, Caparrotti, Giuseppe, Turrini, Mauro, Arcaini, Luca, Santini, Simone, Cerqueti, Manuela, Ferreri, Andres J. M., Cantore, Nicola, Inzoli, Alessandro, Cardinale, Giovanni, Ronci, Benedetto, La Nasa, Giorgio, Massimi, Stefano, Gaglione, Gianfranco, Barbiero, Valentina, Martelli, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813238/
https://www.ncbi.nlm.nih.gov/pubmed/35126524
http://dx.doi.org/10.1155/2022/5581772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813238/
https://www.ncbi.nlm.nih.gov/pubmed/35126524
http://dx.doi.org/10.1155/2022/5581772

Ejemplares similares